The Makers of TYLENOL® Support Students Pursuing Healthcare Related Degrees with 40 Scholarships
FORT WASHINGTON, Penn., March 12, 2012 – McNeil Consumer Healthcare Division of McNEIL-PPC, Inc., the makers of TYLENOL®, announces the 22nd annual TYLENOL® Future Care Scholarship program. The 2012 program will award $250,000 in scholarship funds to 40 undergraduate or graduate students pursuing careers in healthcare. Winners will be named TYLENOL® Future Care Scholars and receive awards of $5,000 or $10,000 to help manage the rising cost of education.
“McNeil is committed to supporting the future of healthcare. Our TYLENOL® Future Care Scholarship program has awarded $8.7 million in scholarship funds to more than 6,700 people,” said Denice Torres, President, McNeil Consumer Healthcare. “We are proud to support these exceptional students as they pursue careers dedicated to caring for others.”
TYLENOL® Future Care Scholars will be selected based on leadership qualities, academic performance and community involvement. To be eligible, students must complete at least one year of undergraduate or graduate study by the Spring of 2012 at an accredited two or four year college, university or vocational/technical school.
The application period is now open and submissions must be received by May 31, 2012. Scholarship award decisions will be made in July and awards distributed by August 31st.
To learn more or apply please visit: www.Tylenol.com/Scholarship2012 or text SCHOLAR to 87715
About McNeil Consumer Healthcare
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. markets a broad range of well-known and trusted over-the-counter (OTC) products. McNeil Consumer Healthcare is most widely recognized for TYLENOL®, the leading brand of pain reliever/fever reducer in the adult and pediatric categories. The TYLENOL® line consists of products across a variety of pain categories including: arthritis pain, pain with accompanying sleeplessness and symptoms of cold and flu. Other McNeil Consumer Healthcare brands include BENADRYL®, ZYRTEC® and ZYRTEC-D® allergy medicines; IMODIUM® anti-diarrheal products; MOTRIN® IB; and SUDAFED® and SUDAFED PE® nasal decongestants.